Ion Channel Modulators
•10 stocks
•
Total Market Cap: Loading...
Market Cap Distribution
Price Performance Heatmap
5Y Price (Market Cap Weighted)
All Stocks (10)
%
| Company | Market Cap | Price |
|---|---|---|
|
JOURNAVX and VX-993 are NaV1.8 inhibitors, a class of ion channel modulators for pain pathways.
|
$104.72B |
$407.79
-1.34%
|
|
Osavampator (AMPA modulator) and other muscarinic/NMDA pathway programs place the company in ion channel/modulator spaces (glutamatergic signaling).
|
$14.51B |
$146.95
+0.38%
|
|
Some Axsome compounds function via NMDA/ion-channel modulation, aligning with Ion Channel Modulators.
|
$5.99B |
$121.71
-0.66%
|
|
ACP-711 targets the GABAA-α3 receptor, representing ion channel modulation as a therapeutic approach.
|
$3.52B |
$21.05
-0.94%
|
|
Ion channel modulators as a class represent a distinct investable theme given Xenon’s Kv7/Nav1.x programs.
|
$3.04B |
$39.64
-4.34%
|
|
Directly applies to Kv7 ion channel modulation and TRPM3 antagonism platforms powering CNS, pain, and neuroimmune programs.
|
$1.61B |
$15.80
-9.97%
|
|
RAP-219 is an AMPA receptor NAM and RAP programs include nicotinic receptor modulators, representing Ion Channel Modulators in CNS.
|
$967.19M |
$26.50
-1.08%
|
|
Praxis' small-molecule assets act as ion channel modulators (T-type Ca2+ and Nav channels) to modulate neuronal excitability.
|
$859.98M |
$47.67
-1.37%
|
|
Auxora is a CRAC channel inhibitor, positioning CalciMedica as a provider of ion channel modulating therapeutics.
|
$44.22M |
$3.17
-6.36%
|
|
Ketamir-2 is an oral ketamine analog, which implicates ion-channel/modulator activity (NMDA receptor).
|
$21.32M |
$1.26
-6.67%
|
Loading industry metrics...
Loading comparison data...
